Fig. 2 | Nature Communications

Fig. 2

From: Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration

Fig. 2

Spironolactone and eplerenone reduce CNV in a rat nAMD model. a Spironolactone (Spiro) significantly reduces the CNV angiographic grades evaluated on fluorescein angiography (FA) (p = 0.0025) and the CNV volume labeled with FITC-isolectin (green) (p = 0.002) as compared to the control group (Ctrl). Infrared images (IR) are used to localize and check the efficient laser-induced burns. The effect of spironolactone is not different from anti-VEGF in reducing the choroidal neovascular leakage on FA and inhibiting the CNV in rat choroidal flat-mounts. Combining the two treatments allows an enhanced effect in reducing vascular permeability compared to anti-VEGF alone (p = 0.0335). b Eplerenone, a more specific MR antagonist, given orally, significantly reduces CNV angiographic grades (p = 0.0012) and CNV volumes (p < 0.0001). Bars: 100 µm. FA Data are expressed as the incidence of CNV angiographic grades of the total laser impacts in each group. CNV volumes are expressed as mean ± SEM of average CNV size per rat. n represents the number of rats. Linear mixed model was used for statistical analyses. *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page